Drug Profile
Research programme: influenza therapy - Amyxa Pharmaceuticals
Alternative Names: APP-0206; CXF-Y2Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Amyxa Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA
- 23 Jun 2009 This programme is still active
- 23 Jun 2009 Aphios Corporation is seeking development partners for the programme (http://www.aphios.com)